Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Offidani

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Leukemia|December 24, 2016
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysisF Gay, S Oliva, M T Petrucci, et al.
Leukemia|October 23, 2015
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active diseaseE Zamagni, C Nanni, F Gay, et al.
Leukemia|February 23, 2016
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myelomaA Larocca, S Bringhen, M T Petrucci, et al.
Leukemia|July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)R Hájek, T Masszi, M T Petrucci, et al.
Dermatology and Therapy|January 11, 2021
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus RecommendationsPaolo Gisondi, Marina Talamonti, Andrea Chiricozzi, et al.
ESMO Open|January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patientsE A Martino, S Palmieri, M Galli, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Leukemia|December 24, 2016
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysisF Gay, S Oliva, M T Petrucci, et al.
Leukemia|October 23, 2015
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active diseaseE Zamagni, C Nanni, F Gay, et al.
Leukemia|February 23, 2016
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myelomaA Larocca, S Bringhen, M T Petrucci, et al.
Leukemia|July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)R Hájek, T Masszi, M T Petrucci, et al.
Dermatology and Therapy|January 11, 2021
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus RecommendationsPaolo Gisondi, Marina Talamonti, Andrea Chiricozzi, et al.
ESMO Open|January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patientsE A Martino, S Palmieri, M Galli, et al.
Pageof 6